Skip to main content
SpringerLink
Log in

Genetics affect risk of bleeding with oral anticoagulants

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. novel (non-vitamin K antagonist) oral anticoagulants

References

  1. Mega JL, et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet : 11 Mar 2015. Available from: URL: http://dx.doi.org/10.1016/S0140-6736(14)61994-2.

  2. Wu AHB. Pharmacogenomic testing and response to warfarin. Lancet : 11 Mar 2015. Available from: URL: http://dx.doi.org/10.1016/S0140-6736(14)62219-4.

  3. Ruff CT, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet : 11 Mar 2015. Available from: URL: http://dx.doi.org/10.1016/S0140-6736(14)61943-7.

  4. Patel MR, et al. Edoxaban and the need for outcomes-based NOAC dosing. Lancet : 11 Mar 2015. Available from: URL: http://dx.doi.org/10.1016/S0140-6736(14)62289-3.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Genetics affect risk of bleeding with oral anticoagulants. Reactions Weekly 1544, 10 (2015). https://doi.org/10.1007/s40278-015-8857-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-015-8857-0

Search

Navigation